myTomorrows Secures $29 Million to Expand AI-Powered Platform for Pre-Approval Treatment Access
核心洞察
myTomorrows (搜索) raised $29 million from Avego (搜索) to scale its AI-driven platform connecting patients with pre-approval treatments including clinical trials and expanded access programs.
The health technology company has already helped over 16,900 patients access therapies across 133 countries, addressing the needs of 300 million patients worldwide without approved treatment options.
The investment will accelerate international expansion and strengthen partnerships with BioPharma companies to streamline clinical development timelines and enhance real-world data capabilities.
myTomorrows (搜索), a health technology company focused on connecting patients with pre-approval treatments, announced the completion of a $29 million financing round led by Avego (搜索). The Amsterdam-based company plans to use the growth equity investment to expand its AI-driven platform globally and strengthen partnerships with BioPharma companies to improve patient access to experimental therapies.
The funding addresses a critical healthcare challenge: more than 300 million patients worldwide face conditions without approved treatment options, while over 10,000 therapies are currently in development or awaiting regulatory approval. myTomorrows (搜索)' platform bridges this gap by facilitating access to pre-approval treatments, including clinical trials and expanded access programs (EAPs).
Platform Performance and Global Reach
myTomorrows (搜索) has demonstrated significant impact since its founding in 2012, helping more than 16,900 patients access therapies across 133 countries. The platform has connected 2,800 physicians across 340+ sites worldwide, establishing itself as what the company describes as "the world's most comprehensive AI-powered platform for pre-approval treatments."
The technology combines AI-driven insights with human expertise to provide patients and physicians with expert navigation services, treatment matching, and streamlined access to clinical trials and expanded access programs. For BioPharma partners, the platform offers clinical trial recruitment, expanded access solutions, and real-world data collection capabilities.
Strategic Investment and Growth Plans
"This investment marks a pivotal step in our journey to give every patient, no matter where they live, a fair shot at tomorrow's therapies," said Michel van Harten, CEO of myTomorrows (搜索). "Avego (搜索)'s extensive expertise in life sciences, particularly BioPharma, will be instrumental as we scale our platform and broaden our impact across the global health landscape."
The new funding will accelerate myTomorrows (搜索)' international expansion and further develop its AI-driven global platform. The investment will also strengthen collaborations with industry partners to shorten clinical development timelines and enhance real-world data capabilities, supporting evidence generation and regulatory insight.
James Flexner, Managing Partner at Avego (搜索), emphasized the strategic value of the partnership: "Avego is proud to support myTomorrows (搜索) in its mission to transform how patients and physicians access therapies in development. We believe myTomorrows is uniquely positioned to remove barriers for patients and providers while serving as an essential partner to BioPharma."
Technology and Infrastructure Development
The platform serves as a unified referral management system for trial sites, enhancing trial visibility and enabling real-time status updates. By connecting all stakeholders across the healthcare ecosystem, myTomorrows (搜索) aims to accelerate the delivery of new therapies to patients in need.
Ronald Brus, Founder and Board Member of myTomorrows (搜索), reflected on the company's evolution: "When we founded myTomorrows in 2012, we envisioned a better way to connect patients with promising therapies - one that complements drug development and expands access to innovation. This investment marks the beginning of a next phase of accelerated growth and worldwide impact."
Future Healthcare Infrastructure
myTomorrows (搜索) positions itself as building infrastructure for what it calls "a new era of treatment access" characterized by AI-enabled transformation, adaptive regulation, and empowered patients who take an active role in their care. The platform is embedded within healthcare systems worldwide, providing what the company describes as "clear, unbiased, and actionable pathways to emerging therapies."
Avego (搜索), founded in 2015 by former healthcare entrepreneurs, operates as a multi-strategy healthcare-focused investment firm with offices in New York and Georgia. The firm invests in private and public companies developing and commercializing innovative products and services across the healthcare continuum through private equity, venture capital, and long/short fund strategies.